EIP Pharma Inc

Industry · 9 registered clinical trials — 2 currently recruiting.

Status	Trial	Phase	Started
Recruiting	Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia Nonfluent Variant Primary Progressive Aphasia (nfvPPA)	Phase 2	2025-10-02
Recruiting	A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke Moderate to Severe Acute Ischaemic Stroke, Ischaemic Stroke	Phase 2	2025-06-20
Completed	A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies Dementia With Lewy Bodies (DLB)	Phase 2	2024-10-16
Completed	RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies Dementia With Lewy Bodies	Phase 2	2023-05-01
Completed	Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies Dementia With Lewy Bodies (DLB)	Phase 2	2019-09-30
Terminated	Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease Huntington Disease	Phase 2	2019-07-08
Completed	Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer' Alzheimer Disease	Phase 2	2017-12-29
Completed	A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease Alzheimer's Disease, Mild Cognitive Impairment	Phase 2	2015-04-01
Completed	Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Dis Alzheimer's Disease	Phase 2	2015-04-01